Bibliometric Analysis of the Hundred Most-Cited Publications on Bone Metastases Research

DOI: https://doi.org/10.21203/rs.3.rs-129834/v1

Abstract

Background

Bone metastases (BM) represents a common complication of cancer, patients with BM may experience skeletal complications, such as pathological fractures, spinal cord compression, hypercalcemia, and persisting pain. Currently, there are a large number of publications available on this topic. The purpose of this study was to identify and analyze the 100 most-cited publications on BM research.

Method

All databases from the Web of Science were searched in a three-step approach. First, the 100 most-cited BM studies were identified using only one term “bone metastases” to allow for comprehensive keyword identification. Second, ten keywords identified from the results of the first search were used to conduct a second search of the databases to yield a separate list of the top 100 cited BM publications. Finally, the results of the two searches were overlapped and duplicated articles were removed. After overlapping, the top 100 most-cited articles on BM were selected for further analysis of title, authorship, source journal, publication year, geographic origin, research institution, number of citations, and subspecialty.

Results

The 100 most-cited articles were published from 1959 to 2014 in 44 different journals and were cited from 250 to 1707 times. The most influential period was from 2001–2010, which produced 50 out of the top 100 publications. A total of 12 countries contributed to the 100 articles, and the United States topped the list with 48 articles. The majority of publications were in Journal of Clinical Oncology, which published 16 articles. In terms of institutional support, a total of 13 institutions each supported at least 2 articles, and the first ranked institution was University of Texas M. D. Anderson Cancer Center (USA) with 8 articles. Regarding subspecialty of the studies, the most frequent studies were “clinical description” with 30 articles, followed by “clinical trial” with 20 articles.

Conclusion

In this comprehensive review, we identified and analyzed the 100-most-cited articles on BM research by measuring their citation number, and recognized some of the most important contributions by authors, institutions and countries. Furthermore, our study will help researchers and orthopedic surgeons understand the research trends for BM and as an efficient guide for future BM-related research. 

Introduction

Bone metastases (BM) represents a common complication in the most prevalent human cancers, whose incidence reaches 70–95% in multiple myeloma (MM), up to 65–90% in prostate cancer (PC), 65–75% in breast cancer (BC), 17–64% in lung cancer (LC), and 10% in colorectal cancer (CC) [1-4]. Patients with BM may experience skeletal complications including pathological fractures, hypercalcemia, spinal cord and nerve compression syndromes, and uncontrolled pain that require orthopedic surgery or/and radiotherapy, collectively referred to as skeletal-related events (SREs) [5,6]. These events seriously affect the quality of life (QoL) of patients and patient survival rates [7]. Therefore, the major treatment options for BM patients aim at improving the QoL and reducing SREs. Currently, BM treatments include loco-regional and systemic approaches. The former, mainly represented by focal excision and radiotherapy, are usually performed to relieve bone pain and to prevent pathological fractures. The latter mainly include anabolic agents, inhibitors of bone resorption and radiopharmaceuticals that aim at restoring severely impaired physiological bone turnover in metastatic bone disease patients [8].

In recent years, with the emergence of imaging techniques with improved sensitivity and specificity in the detection of bone injury, the early diagnosis of BM has significantly improved [9]. The diagnosis and management of BM has also gained much interest among surgeons, similarly, fundamental scientific research has also made major breakthroughs in understanding the mechanism involved in the development of BM. Concomitantly, a large number of studies regarding BM have been published.

Bibliometric analysis is a widely accepted approach for identifying high impact scientific studies on medicine and to quantitatively and qualitatively evaluate its academic impact [10,11] This analysis method has been widely performed in the field of orthopedic surgery [12-16]. To the best of our knowledge, there have been no reports on bibliometric analysis on BM to date. Therefore, our objective was to identify the top 100 most-cited studies on BM, and to analyze the characteristics and research trends of the most impactful publications. This bibliographic analysis will augment efforts in research consensus and will enable researchers to better align their research direction to address the issues that require additional research due to the lack of evidence and to tailor their future research on BM.

Materials And Methods

Inclusion Criteria

All available journals from the Web of Science database were searched to identify and analyze the 100 most-cited articles on BM between 1950 and 2020. To be considered for the top 100 list: (1) papers had to focus on the field of BM; (2) papers should be written in English; and (3) the publication date should be between the 1950 and 2020.

Exclusion Criteria

The exclusion criteria included: (1) papers that focused on broad areas with no emphasis on BM; and (2) papers focused on primary bone/spinal tumor.

Search strategy and study selection

As of 5 July 2020, we identified the 100 most-cited BM research studies published between 1950 and 2020, excluding non-English language studies. In order to achieve a higher comprehensiveness and accurateness of the study, a three-step approach was adopted to search the databases of the Web of Science, as shown in the flow chart in Figure 1.

First, the Web of Science databases was searched using the keyword “bone metastases.” The search produced 85,957 results, which were then ranked in descending order of the total number of citations. In the initial 1200 studies identified, the 100 most-cited papers on BM were selected based on titles and abstracts. The aim was to provide a more comprehensive study of BM, and the title and abstract of the identified 100 studies were systematically analyzed for possible keywords. Combined with other keywords known to be relevant to the field of BM research, a search query composed of a group of 10 keywords was established and used for a second database search by topic. The 10 keywords identified were “bone metastases,” “bone metastasis,” “metastatic bone disease,” “skeletal metastases,” “spinal metastases,” “spinal metastasis,” “metastatic spine disease,” “osseous metastases,” “osteolytic metastases,” and “osteoblastic metastases.”

Second, every search word or phrase was delimited by an OR term, by this means, additional search results were obtained. The second search showed 105,159 results, again were ranked these in descending order of the total number of citations. Of the top 1000 preliminary studies, 100 articles related to BM were selected based on titles and abstracts.

Third, the studies of the two selections were compared, and duplicate studies were removed and the 100 most-cited BM studies were selected for finally analysis.

To ensure consistency of data extraction, two independent authors evaluated the articles for their relevance to BM and the 100 most-cited articles on BM were finial determined. Finally, the 100 most-cited articles were then extracted with regard to basic information including: title, authorship, source journal, publication year, geographic origin, research institution, number of citations, and subspecialty.

Statistical Methods

All data were manually extracted from the Web of Science database and recorded in Microsoft Excel 2016 or further analysis or visualization. VOSviewer (Leiden University, Leiden, the Netherlands) is a commonly used software tool for creating maps for network analysis and visualization. In this study, this software was used to visualize the relationships and the time distribution between the most frequently occurring concepts and keywords.

Results

Overview of publications

The 100 most-cited articles involving BM research were cited from 250 to 1707 times in 44 different journals and the mean citation number was 467.5 (Table 1). “A multigenic program mediating breast cancer metastasis to bone,” published by Kang et al., was the most-cited article (cited 1707 times). The earliest published article was “Experiences with metastatic neoplasms involving the spinal cord,” which was published in 1959 by Barron et al. (cited 312 times). The most recent article was “Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial,” published by Sartor et al. in 2017 (cited 312 times).

Country of publications

The top 100 articles originated from 12 different countries. Authors from the United States contributed 48 articles. European centers from ten countries published 34 articles in total. Among these, 10 articles were from the United Kingdom, 8 articles were from France, 3 articles were from Italy, Sweden, and The Netherlands, 2 articles were from Switzerland and Belgium, and 1 article was from Austria, Denmark and Germany. Authors from Asia and Africa published relatively fewer articles compared to the United States and Europe. Authors from Japan published 5 articles, and Israel 1 articles, respectively. Besides, authors from Canada and Australia published 10 and 1 articles, respectively.

Year of publication

The publishing period responsible for the largest number of studies was 2001 to 2010 with 50 articles, followed by 1991 to 2000 with 24 articles, 1981 to 1990 with 11 articles, 2011 to 2014 with 10 articles, and the period 1971 to 1980 with 3 articles (Figure 3). Notably, only 2 articles were published before 1970.

Journals of publications

Overall, 44 different journals were represented on the list of the 100 most-cited studies (Table 2). The Journal of Clinical Oncology was the most popular journal, which was responsible for 16 articles and 7218 total citations. This was followed by Cancer with 10 articles with 4888 total citations. Cancer Research, Spine, Journal of Neurosurgery, Journal of the National Cancer Institute, and Cancer Cell each with 4, 4, 3, 3 and 3 articles, respectively. Although there were only 2 articles on the list which were published in Lancet, their mean citations per article was the highest (1106 times per article).

Authors of publications

Regarding the authors, A Lipton was the most productive author with 11 articles in total, followed by R. E. Coleman with 11 articles. J. E. Brown, G. N. Hortobagyi, F. Saad, J. J. Seaman, J. J. Body, and L. S. Rosen, with 5 articles each (Table 3).

Institutions of publications

In terms of institutional support, a total of 13 institutions each supported at least 2 articles (Table 4). The first ranked institution was the University of Texas M. D. Anderson Cancer Center (USA) with 8 articles. The second top ranked institution was Weston Park Hospital with 5 articles. The Memorial Sloan-Kettering Cancer Center (USA), and the University of Toronto (Canada) were tied for third with 4 articles each.

Subspecialty of publications

Regarding the subspecialty of the studies, the most frequent studies were “clinical description” (n=30), followed by “clinical trial” (n=20), “mechanism” (n=16), “drug efficacy” (n=11) “radiotherapy” (n=7), “evaluation” (n=5), “surgery treatment” (n=4), “detection” (n=3), “murine model” (n=2), and “prediction” (n=2) (Figure 4).

Keyword analysis of publications

As shown in Figure 5, the 28 terms (defined as being used more than 6 times within titles and abstracts in all of the articles) were classified into 3 clusters: “clinical trial”, “clinical features”, and “basic research”. Among the “clinical trial” cluster, keywords used in the top articles were listed as follows: trial (30 items), time (26 items), event (23 items), week (22 items), and spinal cord compression (20 items). For the cluster of “clinical features”, the primary keywords were as follows: treatment (61 items), survival (29 items), pain (29 items), year (27 items), and site (21 items). In the “basic research” cluster, the primary keywords were as follows: cell (35 items), factor (25 items), breast cancer (25 items), effect (24 items), and therapy (22 items).

As shown in Figure 6, VOSViewer assigned colors to keywords according to the average year in which they appeared in the article. In the early stage of BM research, both the biological and clinical fields were the main hotspots. In the early stage of BM research, treatment of BM was the main hotspot. Recent trends showed that the words “SRE”, “zoledronic acid”, “hazard rate”, “denosumab”, and “intension” appeared as keywords articles after 2006. There was most of the key words appear in the “clinical trial” cluster.

Discussion

The present bibliometric analysis determined and characterized the 100 most-cited publications in the Web of Science databases. After identifying the most-cited research articles, we obtained insight into the historic developmental trends in BM research that reflected the great importance and academic concern placed on the study of BM.

Undoubtedly the publishing date will affect citation numbers, the longer periods after the article is published allows for a greater opportunity to be cited. In our study, the most productive period was from 2001 to 2010 with 50 articles. However, only 2 articles were published before 1970. This indicates that the improvement of BM research quality and efficiency promoted an increase in papers and citations in recent years. Notably, no top-cited articles were published after 2015 in our current analysis. We speculated the following possible reasons for this: firstly, because BM has always been a hot research field for researchers and orthopedic surgeons, numerous high-quality articles have already been published, although, we have only included the top 100 most-cited articles, therefore, articles with relatively fewer citations are not included. Secondly, more recently published articles need time to be cited widely.

In total, 44 different journals published the top 100 most-cited studies, with the Journal of Clinical Oncology contributing most studies, followed by Cancer. It has been reported that major journals can attract high-quality research articles in their fields, maintaining high the impact factors of these journals [17]. Compared with other similar bibliometric studies, top 100 articles have been published in a greater number of journals, while, the most contributive journals have published fewer articles [18,19]. We speculated that this may be related to more high-quality journals in the field of cancer.

Overall, 12 different countries contributed to the top 100 articles, and the most productive country of article origin was the United States, followed by European centers. In contrast, Asia (Japan, Israel) made a relatively small contribution to the 100 most-cited articles, which indicated that there is still a large gap of scientific studies published between Asian countries and western developed areas. Thus, various countries, especially in developing regions, have to endeavor make greater contributions to be integrated into the world scientific processes.

VOSviewer software was used to analyze the keywords of the main subjects of these 100 articles. The 100 most-cited articles extracted from all database of the Web of Science were classified into 3 clusters: “clinical trial,” “clinical features,” and “basic research.” In the clinical trial cluster, “trial” and “time” were the most frequently appearing keywords on the network map. This finding demonstrated that randomized controlled trials investigating drug therapy are a major research direction in the field of BM. In the clinical features cluster, the most frequently occurring keywords included “treatment,” “survival,” and “pain” meaning that the clinical efficacy and prognosis of BM patients have been widely studied. Further, in the basic research cluster, “cell,” “factor,” and “breast cancer” were the most frequently keywords, which illustrated that the research interest was mainly focused on the molecular biology of BM. Generally, molecular mechanisms, treatment, and prognosis were hot topics in the research of BM.

Keyword analysis is an indispensable approach to evaluate the evolution of research hotspots in this field. To the best of our knowledge, this study is the first to visually summarize the evolution of global research trends on BM. Among the 3 keyword clusters “clinical trial,” “clinical features,” and “basic research,” the former is of great interest because of the obvious changes in the research hotspots over the last 20 years. From simple attention to pain control to a series of clinical problems caused by SREs, researchers and surgeons are focusing increasingly on improving prognosis and prolonging the survival of patients with BM [20,21]. In-depth study of the molecular mechanisms, targeted therapies, and immunotherapy have attracted increasing attention, and some studies have led to agents being recommended as first-line drugs by the guidelines, such as denosumab [22]. In addition, in recent years, with the rapid progress of radiotherapy research, especially the emergence of stereotactic body radiation therapy (SBRT), radiotherapy has also received strong research interest from doctors and patients [23,24]. Even so, surgery and chemotherapy still play an irreplaceable role. Thus, it is necessary to review the highly quality articles to understand milestones during the study of BM.

Although this current analysis was relatively comprehensive and objective, it had several limitations. First, the date for literature search was 5 July 2020, theoretically, which could limit the citation numbers by time. Second, besides the Web of Science, Google Scholar and SCOPUS databases could also provide citation data, these databases may display a different number of citations and therefore may provide different analysis results [25].Third, since the top 100 articles selected are limited to English, we might have overlooked high-impact articles in other languages. Finally, some recently published high-quality articles were not included in this analysis due to their low citation frequency.

In summary, despite its limitations, bibliometric analysis remains one of the best methods to quantify the impact of scientific studies and to quantify the contributions of researchers [26,27]. We believe that this study highlights a series of intellectual milestones in BM research. The present study identified influential authors, institutions, countries, and journals that have made outstanding contributions to BM research. Undoubtedly, this study will provide a catalogue of valuable articles for young researchers and will help scientists to master research hotspots and to determined future academic pursuits.

Conclusion

The BM literature has grown continuously over the years. The 100 most-cited publications in BM research were searched and analyzed, and the contribution of the authors and their origins were identified. This article provides insight into the development of BM research, and should contribute to help scientists to grasp the international research hotspots on BM research.

Abbreviations

BM: bone metastases

MM: multiple myeloma

PC: prostate cancer

BC: breast cancer

LC: lung cancer

CC: colorectal cancer

SREs: skeletal-related events

QoL: quality of life

SBRT: stereotactic body radiation therapy

Declarations

Acknowledgements

Not applicable.

Author’s contributions

Conceived and designed the study: Yao Kang and Jun Zhang. Revised the protocol: Tingxiao Zhao and Yuan Zhang. Extracted the data: Jun Lv, Meng Ge and Yazeng Huang. Performed the statistical analysis: Zhanqiu Dai, Haiyu Shao, and Xiaoyan Ding. Wrote the manuscript: Tingxiao Zhao and Yuan Zhang. All authors contributed constructive comments on the paper. The authors read and approved the final manuscript.

Funding

This study was supported by grants from The Graduate Research and Innovation Program of Bengbu Medical College (Byycx1906 to Dr. Tingxiao Zhao ).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Ethics approval is not required due to this work is carried out on open data.

Consent for publication

Not applicable.

Competing Interests:

The authors declare that they have no competing interests.

Device Status/Drug Statement:

The manuscript submitted does not contain information about medical devices

References

  1. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res (2007) 31:129-38.
  2. Sousa S, Clézardin P. Bone-targeted therapies in cancer-induced bone disease. Calcif Tissue Int (2018) 102:227-50.
  3. D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol (2018) 15:004-4.
  4. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: An overview. Oncol Rev. (2017) 11:321.
  5. Kan C, Vargas G, Pape FL, Clézardin P. Cancer cell colonisation in the bone microenvironment. Int J Mol Sci (2016) 17:1674.
  6. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 12:6243s-9s.
  7. McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist (2016) 21:320-6.
  8. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 12:6243s-9s.
  9. Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol (2018) 19:e534-45.
  10. Larsen PO, von Ins M. The rate of growth in scientific publication and the decline in coverage provided by Science Citation Index. Scientometrics (2010) 84:575-603.
  11. Garfield E. Citation analysis as a tool in journal evaluation. Science (1972) 178:471-9.
  12. Huang W, Wang L, Wang B, Yu L, Yu X. Top 100 cited articles on back pain research: a citation analysis. Spine (Phila Pa 1976) (2016) 41:1683-92.
  13. Rüegsegger N, Ahmad SS, Benneker LM, Berlemann U, Keel MJ, Hoppe S. The 100 Most influential publications in cervical spine research. Spine (Phila Pa 1976) (2016) 41(6):538-48.
  14. Virk SS, Yu E. The Top 50 articles on minimally invasive spine surgery. Spine (Phila Pa 1976) (2017) 42:513-9.
  15. Murray MR, Wang T, Schroeder GD, Hsu WK. The 100 most-cited spine articles. Eur Spine J (2012) 21:2059-69.
  16. De la Garza-Ramos R, Benvenutti-Regato M, Caro-Osorio E. The 100 most-cited articles in spinal oncology. J Neurosurg Spine (2016) 24:810-23.
  17. Ioannidis JP. Concentration of the most-cited papers in the scientific literature: analysis of journal ecosystems. PLoS One (2006) 1:e5.
  18. Zhao T, Shen J, Zheng B, Huang Y, Jin M, Morizane K, et al. The 100 most-cited publications in endoscopic spine surgery research. Global Spine J (2020) 2192568220934740.
  19. Huang Y, Zhao T, Reidler JS, Chen X, Zhang H, Shao H, et al. The Top 100 Most-cited articles on kyphoplasty and vertebroplasty. World Neurosurg (2020) 135:e435-46.
  20. Sun XS, Lin C, Liang YJ, Chen QY, Tang LQ, Mai HQ. Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis. Oral Oncol (2019) 97:31-6.
  21. Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, et al. The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice. Oncol Lett (2018) 16:7195-203.
  22. Link H, Diel I, Ohlmann CH, Holtmann L, Kerkmann M. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Support Care Cancer (2020) 28(5):2175-84.
  23. Ito K, Yamaguchi T, Ogawa H, Nakajima Y, Karasawa K. Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Jpn J Clin Oncol (2020) hyaa128.
  24. Nguyen TK, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, et al. Stereotactic body radiation therapy for nonspine bone metastases: international practice patterns to guide treatment planning. Pract Radiat Oncol (2020) S1879-8500(20)30056-4.
  25. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA (2009) 302:1092-6.
  26. Larsen PO, von Ins M. The rate of growth in scientific publication and the decline in coverage provided by Science Citation Index. Scientometrics (2010) 84:575-603.
  27. Garfield E. Citation analysis as a tool in journal evaluation. Science (1972) 178(4060):471-9.

Tables

 

TABLE 1. The Top 100 Cited Articles on Bone Metastases

Rank

Author

Title

Journal

Year

Citation

Citation No./Year

1

Kang, Y. B.

A multigenic program mediating breast cancer metastasis to bone

Cancer Cell

2003

1707

100.41

2

Roodman, G. D.

Mechanisms of disease: mechanisms of bone metastasis

New England Journal of Medicine

2004

1347

84.19

3

Coleman, R. E.

Clinical features of metastatic bone disease and risk of skeletal morbidity

Clinical Cancer Research

2006

1122

80.14

4

Patchell, R. A.

Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial

Lancet

2005

1115

74.33

5

Fizazi, K.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Lancet

2011

1097

121.89

6

Coleman, R. E

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

Cancer Treatment Reviews

2001

1048

55.16

7

Coleman, R. E.

Skeletal complications of malignancy

Cancer

1997

1011

43.96

8

Stopeck, A. T.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

Journal of Clinical Oncology

2010

839

83.90

9

Saad, F.

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

Journal of the National Cancer Institute

2004

784

49.00

10

Taichman, R. S.

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone

Cancer Research

2002

761

42.28

11

Coleman, R. E.

The clinical course of bone metastases from breast cancer

British Journal of Cancer

1987

755

22.88

12

Hortobagyi, G. N.

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

The New England Journal of Medicine

1996

746

31.08

13

Yin, J. J.

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

Journal of Clinical Investigation

1999

692

32.95

14

Hillner, B. E.

American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

Journal of Clinical Oncology

2003

688

40.47

15

Tomita, K.

Surgical strategy for spinal metastases

Spine

2001

642

33.79

16

Gilbert, R. W.

Epidural spinal cord compression from metastatic tumor: diagnosis and treatment

Annals of Neurology

1978

637

15.17

17

Henry, D. H.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

Journal of Clinical Oncology

2011

631

70.11

18

Rosen, L. S.

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial

Cancer Journal

2001

618

32.53

19

Cotten, A.

Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up

Radiology

1996

615

25.63

20

Rosen, L. S.

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trialarative trial

Cancer

2003

595

35.00

21

Weilbaecher, K. N.

Cancer to bone: a fatal attraction

Nature Reviews Cancer

2011

577

64.11

22

Thalmann, G. N.

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer

Cancer Research

1994

560

21.54

23

Fleisch, H.

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

Drugs

1991

558

19.24

24

Mercadante, S.

Malignant bone pain: pathophysiology and treatment

Pain

1997

553

24.04

25

Tong, D.

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

Cancer

1982

537

14.13

26

Weill, A.

Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement

Radiology

1996

524

21.83

27

Tokuhashi, Y.

A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis

Spine

2005

520

34.67

28

Even-Sapir, E.

The detection of bone metastases in patients with high-risk prostate cancer: Tc-99m-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, F-18-fluoride PET, and F-18-fluoride PET/CT

Journal of Nuclear Medicine

2006

518

37.00

29

Jones, D. H.

Regulation of cancer cell migration and bone metastasis by RANKL

Nature

2006

500

35.71

30

Chow, E.

Palliative radiotherapy trials for bone metastases: A systematic review

Journal of Clinical Oncology

2007

497

38.23

31

Boissier, S.

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

Cancer Research

2000

482

24.10

32

Rosen, L. S.

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group

Journal of Clinical Oncology

2003

473

27.82

33

Lutz, S.

Palliative radiotherapy for bone metastases: an astro evidence-based guideline

International Journal of Radiation Oncology Biology Physics

2011

473

52.56

34

Lipton, A.

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials

Cancer

2000

469

23.45

35

Soloway, M. S.

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

Cancer

1988

459

14.34

36

Fourney, D. R.

Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients

Journal of Neurosurgery

2003

453

26.65

37

Hortobagyi, G. N.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

Journal of Clinical Oncology

1998

445

20.23

38

Theriault, R. L.

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial

Journal of Clinical Oncology

1999

439

20.90

39

Hartsell, W. F.

Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases

Jnci-Journal of the National Cancer Institute

2005

438

29.20

40

Gerszten, P. C.

Radiosurgery for spinal metastases - Clinical experience in 500 cases from a single institution

Spine

2007

438

33.69

41

Paterson, A. H.

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

Journal of Clinical Oncology

1993

437

16.19

42

Rosen, L. S.

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial

Cancer

2004

434

27.13

43

Zhang, X. H.

Latent bone metastasis in breast cancer tied to src-dependent survival signals

Cancer Cell

2009

424

38.55

44

Mundy, G. R.

Mechanisms of bone metastasis

Cancer

1997

413

17.96

45

Steenland, E.

The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study

Radiotherapy and Oncology

1999

411

19.57

46

Schlumberger, M.

Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma

The Journal of Clinical Endocrinology and Metabolism

1986

406

11.94

47

Brown, J. E.

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

Jnci-Journal of the National Cancer Institute

2005

392

26.13

48

Coleman, R. E.

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

Journal of Clinical Oncology

2005

379

25.27

49

Kang, Y. B.

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

Proceedings of the National Academy of Sciences of the United States of America

2005

370

24.67

50

Tokuhashi, Y.

Scoring system for the preoperative evaluation of metastatic spine tumor prognosis

Spine

1990

367

12.23

51

Cook, G. J.

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

Journal of Clinical Oncology

1998

361

16.41

52

Fizazi, K.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates

Journal of Clinical Oncology

2009

359

32.64

53

Berenson, J. R.

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. A double-blind, randomized dose-response study

Cancer

2001

353

18.58

54

Goetz, M. P.

Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study

Journal of Clinical Oncology

2004

352

22.00

55

Logothetis, C. J.

Osteoblasts in prostate cancer metastasis to bone

Nature Reviews Cancer

2005

352

23.47

56

Wu, J. S. Y.

Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases

International Journal of Radiation Oncology Biology Physics

2003

350

20.59

57

Nielsen, O. S.

Bone metastases: pathophysiology and management policy

Journal of Clinical Oncology

1991

349

12.03

58

Saad, F.

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

Cancer

2007

346

26.62

59

Sasaki, A.

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

Cancer research

1995

344

13.76

60

Kohno, N.

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial

Journal of Clinical Oncology

2005

343

22.87

61

Body, J. J.

A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

Clinical Cancer Research

2006

341

24.36

62

Nilsson, S.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Lancet Oncology

2007

339

26.08

63

Young, R. F.

Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy

Journal of neurosurgery

1980

339

8.48

64

Fisher, C. G.

A novel classification system for spinal instability in neoplastic disease an evidence-based approach and expert consensus from the Spine Oncology Study Group

Spine

2010

337

33.70

65

Schlumberger, M.

Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma

Journal of Nuclear Medicine

1996

336

14.00

66

Hamaoka, T.

Bone imaging in metastatic breast cancer

Journal of Clinical Oncology

2004

336

21.00

67

Price, P.

Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases

Radiotherapy and Oncology

1986

333

9.79

68

Saad, F.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Annals of Oncology

2012

323

40.38

69

Mirels, H.

Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures

Clinical Orthopaedics and Related Research

1989

321

10.35

70

Guise, T. A.

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

Clinical Cancer Research

2006

318

22.71

71

Yamada, Y.

High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions

International Journal of Radiation Oncology Biology Physics

2008

315

26.25

72

Chow, E.

Update on the systematic review of palliative radiotherapy trials for bone metastases

Clinical Oncology

2012

312

39.00

73

Barron, K. D.

Experiences with metastatic neoplasms involving the spinal cord

Neurology

1959

312

5.11

74

Sethi, N.

Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells

Cancer Cell

2011

310

34.44

75

Body, J. J.

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

Annals of Oncology

2003

307

18.06

76

Maranzano, E.

Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial

International Journal of Radiation Oncology, Biology, Physics

1995

307

12.28

77

Takeshita, F.

Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo

Proceedings of the National Academy of Sciences of the United States of America

2005

306

20.40

78

Chang, E. L.

Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure

Journal of Neurosurgery-Spine

2007

304

23.38

79

Boucharaba, A.

Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer

Journal of Clinical Investigation

2004

300

18.75

80

Wong, D. A.

Spinal metastases: the obvious, the occult, and the impostors

Spine

1990

299

9.97

81

Hornberg, E.

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Plos One

2011

296

32.89

82

Lipton, A.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

European Journal of Cancer

2012

290

36.25

83

Serafini, A. N.

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

Journal of Clinical Oncology

1998

290

13.18

84

Kingsley, L. A.

Molecular biology of bone metastasis

Molecular Cancer Therapeutics

2007

286

22.00

85

Arguello, F.

A murine model of experimental metastasis to bone and bone marrow

Cancer Research

1988

286

8.94

86

Gu, Z.

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Oncogene

2000

281

14.05

87

Constans, J. P.

Spinal metastases with neurological manifestations. Review of 600 cases

Journal of Neurosurgery

1983

280

7.57

88

Daldrup-Link, H. E.

Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET

American Journal of Roentgenology

2001

275

14.47

89

Nilsson, S.

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

Clinical Cancer Research

2005

273

18.20

90

Chen, T. L.

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

Journal of Clinical Pharmacology

2002

273

15.17

91

Body, J. J.

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Cancer

2003

271

15.94

92

Bendre, M. S.

Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease

Bone

2003

270

15.88

93

Deckers, M.

The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells

Cancer Research

2006

268

19.14

94

Sartor, O.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Lancet Oncology

2014

264

44.00

95

Thalmann, G. N.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis

Prostate

2000

263

13.15

96

Galasko, C. S.

Mechanisms of bone destruction in the development of skeletal metastases

Nature

1976

262

5.95

97

Murray, L. J.

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Clinical & Experimental Metastasis

2003

259

15.24

98

Edelstyn, G. A.

The radiological demonstration of osseous metastases. Experimental observations

Clinical Radiology

1967

259

4.89

99

Lelekakis, M.

A novel orthotopic model of breast cancer metastasis to bone

Clinical & Experimental Metastasis

1999

257

12.24

100

Jacobs, S. C.

Spread of prostatic cancer to bone

Urology

1983

250

6.76

 

TABLE 2. Publishing Years of the Top 100 Cited Articles on Bone Metastases

Publishing Years

Articles

Total Citations

Mean Citations

1959

1

312

312

1967

1

259

259

1971-1980

3

1238

412.67

1981-1990

11

4293

390.27

1991-2000

24

11143

464.29

2001-2010

50

24935

498.7

2011-2014

10

4573

457.3

 

TABLE 3. Journals with More Than One of the Top 100 Cited Articles on Bone Metastases

Journals

Articles

Total Citations

Mean Citations

Impact Factor

Journal of Clinical Oncology

16

7218

451.13

32.956

Cancer

10

4888

488.8

5.742

Cancer research

6

2701

450.17

9.727

Spine

6

2603

433.83

2.646

Clinical Cancer Research

4

2054

513.5

10.107

International Journal of Radiation Oncology Biology Physics

4

1445

361.25

5.859

Journal of Neurosurgery

3

1072

357.33

3.968

Cancer Cell

3

2441

813.67

26.602

Annals of Oncology

2

630

315

18.274

Clinical & Experimental Metastasis

2

516

258

3.037

Journal of the National Cancer Institute

2

830

415

11.577

Journal of Clinical Investigation

2

992

496

11.864

Journal of Nuclear Medicine

2

854

427

7.887

Lancet

2

2212

1106

60.392

Lancet Oncology

2

603

301.5

33.752

Nature

2

762

281

42.778

Nature Reviews Cancer

2

929

464.5

53.03

Proceedings of the National Academy of Sciences of the United States of America

2

676

338

9.412

Radiology

2

1139

569.5

7.931

Radiotherapy and Oncology

2

744

372

4.856

 

TABLE 4. Most Frequent Authors of the 100 Most Cited Articles on Bone Metastases

Authors

Articles

First Author

Last Author

Coauthor

Areas of Interest

Lipton, A.

13

2

0

11

Drug efficacy; Clinical trial; Prediction

Coleman, R. E.

11

5

2

4

Drug efficacy; Clinical trial; Prediction

Brown, J. E.

5

1

0

4

Clinical trial; Prediction

Hortobagyi, G. N.

5

2

0

3

Drug efficacy; Clinical trial; Clinical description

Saad, F.

5

3

0

2

Drug efficacy; Prediction

Seaman, J. J.

5

0

3

2

Clinical trial

Body, J. J.

5

3

0

2

Drug efficacy; Prediction

Rosen, L. S.

5

4

0

1

Clinical trial

Dansey, R.

4

0

1

3

Clinical trial; Clinical description

Fizazi, K.

4

2

0

2

Clinical trial; Clinical description

Gordon, D.

4

0

0

4

Clinical trial

Guise, T. A.

4

1

1

2

Mechanism

Jun, S.

4

0

2

2

Clinical trial

Theriault, R. L.

4

1

0

3

Drug efficacy; Clinical trial

 

TABLE 5. Contributing Institutions with More Than Two of the Top 100 Cited Articles on Bone Metastases

Institutions

Location

Articles

Total Citations

University of Texas M. D. Anderson Cancer Center

 USA

8

3635

Weston Park Hospital

United Kingdom

5

4328

Memorial Sloan-Kettering Cancer Center

USA

4

2816

University of Toronto

Canada

4

1745

Cancer Institute Medical Group

USA

3

1502

University of California

USA

3

1238

University of Texas Health Science Center at San Antonio

USA

3

1449

Centre Hospitalier de l'Université de Montréal

Canada

2

1130

Institut Jules Bordet

Belgium

2

612

Joan Karnell Cancer Center

USA

2

735

Nihon University

Japan

2

887

University of Berne

Switzerland

2

821

University of Virginia

USA

2

604